Emergent Reports Q4 Revenue of $148.7M, Below Consensus
Reports Q4 revenue $148.7M, consensus $217.50M. Revenues from Naloxone products decreased 41% primarily due to increased competition, while Anthrax MCM products increased 64% due to the impact of timing. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," said CEO Joe Papa.